Physician profile
Michael P Sullivan
NPI 1336105626
$1,086.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $127 · 2021: $162 · 2022: $394.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $200.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $124.79 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $117.23 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.82 | 2022 | |
| Biogen, INC. | $96.00 | 2020-2022 | |
| Abbvie INC. | $88.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.94 | 2019 | |
| Genzyme Corporation | $82.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.90 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $41.27 | 2021 | |
| Adamas Pharmaceuticals, INC. | $41.24 | 2019-2020 | |
| Tactile Systems Technology INC | $19.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.29 | 2021 | |
| Medtronic, INC. | $14.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.16 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.